Project Grant R56HL179741
- This $558,045 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate how the enzyme protein phosphatase 2A (PP2A) controls the function of T cells and contributes to the development of systemic lupus erythematosus (SLE). The research aims to determine how PP2A regulates metabolic enzymes involved in...
- The federal Project Grant award of $300,000 was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to Temple University in Philadelphia, PA. The funding supports research focused on understanding the role of the kallikrein-kinin system and its ability to suppress the type I interferon response, which is a hallmark of systemic lupus erythematosus (SLE). The research aims to explore new pathways for interferon suppression and their...
- This Project Grant award in the amount of $997,821.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research on the "Pathogenic Role of Neutrophil Subpopulations in Lupus Nephritis". The primary awardee is the Trustees of Dartmouth College, a prestigious private research university, with sub-awards going to The Johns Hopkins University and Dartmouth-Hitchcock Clinic to assist with the research. The grant...
- This $256,808 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The University of Washington is conducting this research, which focuses on analyzing altered mRNA splicing in SLE neutrophils and exploring the consequences of these splicing changes, including...
- This federal Project Grant award for $3,364,935.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to functionally and mechanistically characterize genetic factors that contribute to the development of systemic lupus erythematosus (SLE). The research aims to elucidate the role of autophagy, a cellular process, in the pathogenesis of SLE, particularly in immune cells and...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $115,414 to the Beckman Research Institute of the City of Hope to conduct research aimed at concurrently eradicating pathogenic plasma cells and their precursors in systemic lupus erythematosus (SLE). The award, which runs from September 2024 to August 2026, will support two specific aims: 1) determining the effect of knockdown of the...
- This federal Project Grant award of $2,989,958 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Thomas Jefferson University's Sidney Kimmel Medical College. The grant supports research to delineate the mechanisms by which pyrimidine synthesis promotes systemic autoimmunity in systemic lupus erythematosus (SLE). The research aims to improve understanding of the role of pyrimidine...
- This federal Project Grant award in the amount of $700,000.00, provided by the National Institute of General Medical Sciences (CFDA 93.859 - Biomedical Research and Research Training program), supports research to investigate the role of the ARID3A protein in systemic lupus erythematosus (SLE) and other autoimmune diseases. The award will fund a research project at the University of Oklahoma Health Sciences Center to: 1) define genes and epigenetic regions directly regulated by ARID3A expression...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $715,957.00 to Northwestern University to conduct research on the mechanisms by which type I interferon cytokines support the production and expansion of T peripheral helper (Tph) cells in systemic lupus erythematosus (SLE) patients. The research aims to elucidate the molecular pathways...
- This federal Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into the functions of the LYNA and LYNB kinases in myeloid-cell pro-inflammatory signaling and their relationship to systemic lupus erythematosus (SLE). The $668,135 award, effective from Sep 1, 2025 to Aug 31, 2030, aims to assess the roles of these kinase...
This Project Grant award for $300,000 from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) supports research on the role of activated neutrophils and T cells in the pathogenesis of systemic lupus erythematosus (SLE), lupus nephritis, and vasculitis. The research aims to investigate how immune cell abnormalities, specifically the generation of antigen-presenting neutrophils (termed NAPCs) that activate self-reactive T cells, contribute to these autoimmune disease processes. The project will utilize mouse models to examine how immune complexes interact with Fc gamma receptors on neutrophils to generate highly immunogenic NAPCs that can expand naive T cells even in the absence of conventional dendritic cells. The project period is from Sep 10, 2025 to Aug 31, 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $300.0k | 9/8/25 |